Juvenile Idiopathic Arthritis clinical trials at UCSF
1 research study open to eligible people
Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
open to eligible people ages 2-17
This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential multiple assignment randomized trial design with 2 randomization stages corresponding with clinical decision points. The first randomization addresses whether each of the 3 non-TNFi medications is superior to treatment with a second TNFi. The second randomization allows identification of optimal sequential use of biologics (treatment strategies).
San Francisco, California and other locations
Our lead scientists for Juvenile Idiopathic Arthritis research studies include Susan Kim.
Last updated: